BACKGROUND & AIMS: Aberrant crypt foci (ACF) are the putative precursor of colorectal adenomas. However, there are limited data available on the prevalence and risk factors for ACF. METHODS: Subjects from the Prostate, Lung, Colorectal and Ovarian cancer screening trial were recruited for an ACF study, with subjects with adenoma history being oversampled. By using a standardized protocol of magnified chromoendoscopy with methylene blue staining (up to the middle rectal fold), ACF were photo-documented and removed for histologic evaluation. RESULTS: A total of 505 (66% male; 55% > or =70 y) subjects from 4 institutions were examined; 42% had no adenoma, 32% had nonadvanced distal adenoma, and 25% had advanced distal adenoma at the baseline Prostate, Lung, Colorectal and Ovarian cancer screening trial examination (8.2 years before ACF examination on average). A total of 68% of this population had 1 or more ACF, 43% had 1 to 3, 19% had 4 to 6, and 5% had 7 or more. Baseline adenoma status was not associated with ACF prevalence (range, 66%-69%) or mean number of ACF (range, 3.1-3.5). Of 143 endoscopic ACF examined histologically, 68.5% were confirmed to be ACF. In a logistic model, current (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.2-5.6) and former smoking (OR, 1.6; 95% CI, 1.1-2.5) were associated with higher ACF prevalence; a body mass index greater than 30 was associated with lower prevalence (OR, 0.53; 95% CI, 0.35-0.8). Age, sex, family history of colorectal cancer, and aspirin/nonsteroidal anti-inflammatory drug use were not associated significantly with ACF prevalence. CONCLUSIONS: ACF prevalence and number were not associated with adenoma history, and only 68.5% of endoscopic ACF were confirmed histologically. These results raise concern about the use of ACF as a surrogate marker of colorectal cancer risk.
BACKGROUND & AIMS: Aberrant crypt foci (ACF) are the putative precursor of colorectal adenomas. However, there are limited data available on the prevalence and risk factors for ACF. METHODS: Subjects from the Prostate, Lung, Colorectal and Ovarian cancer screening trial were recruited for an ACF study, with subjects with adenoma history being oversampled. By using a standardized protocol of magnified chromoendoscopy with methylene blue staining (up to the middle rectal fold), ACF were photo-documented and removed for histologic evaluation. RESULTS: A total of 505 (66% male; 55% > or =70 y) subjects from 4 institutions were examined; 42% had no adenoma, 32% had nonadvanced distal adenoma, and 25% had advanced distal adenoma at the baseline Prostate, Lung, Colorectal and Ovarian cancer screening trial examination (8.2 years before ACF examination on average). A total of 68% of this population had 1 or more ACF, 43% had 1 to 3, 19% had 4 to 6, and 5% had 7 or more. Baseline adenoma status was not associated with ACF prevalence (range, 66%-69%) or mean number of ACF (range, 3.1-3.5). Of 143 endoscopic ACF examined histologically, 68.5% were confirmed to be ACF. In a logistic model, current (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.2-5.6) and former smoking (OR, 1.6; 95% CI, 1.1-2.5) were associated with higher ACF prevalence; a body mass index greater than 30 was associated with lower prevalence (OR, 0.53; 95% CI, 0.35-0.8). Age, sex, family history of colorectal cancer, and aspirin/nonsteroidal anti-inflammatory drug use were not associated significantly with ACF prevalence. CONCLUSIONS: ACF prevalence and number were not associated with adenoma history, and only 68.5% of endoscopic ACF were confirmed histologically. These results raise concern about the use of ACF as a surrogate marker of colorectal cancer risk.
Authors: Paul J Limburg; Michelle R Mahoney; Katie L Allen Ziegler; Stephen J Sontag; Robert E Schoen; Richard Benya; Michael J Lawson; David S Weinberg; Elena Stoffel; Michael Chiorean; Russell Heigh; Joel Levine; Gary Della'Zanna; Luz Rodriguez; Ellen Richmond; Christopher Gostout; Sumithra J Mandrekar; Thomas C Smyrk Journal: Cancer Prev Res (Phila) Date: 2011-01-05
Authors: Paul F Pinsky; James Fleshman; Matt Mutch; Christopher Rall; Aline Charabaty; David Seligson; Sarah Dry; Asad Umar; Robert E Schoen Journal: Cancer Prev Res (Phila) Date: 2010-06-22
Authors: Miguel Angel Ramírez-Ramírez; Sergio Sobrino-Cossío; José Guillermo de la Mora-Levy; Angélica Hernández-Guerrero; Verónica de Jesús Macedo-Reyes; Héctor Aquiles Maldonado-Martínez; Juan Octavio Alonso-Larraga; Mauro Eduardo Ramírez-Solis Journal: J Gastrointest Cancer Date: 2012-06
Authors: David A Drew; Allen Mo; James J Grady; Richard G Stevens; Joel B Levine; Bruce M Brenner; Joseph C Anderson; Faripour Forouhar; Michael J O'Brien; Thomas J Devers; Daniel W Rosenberg Journal: Mol Cancer Res Date: 2017-12-08 Impact factor: 5.852
Authors: Robert E Carroll; Richard V Benya; Danielle Kim Turgeon; Shaiju Vareed; Malloree Neuman; Luz Rodriguez; Madhuri Kakarala; Philip M Carpenter; Christine McLaren; Frank L Meyskens; Dean E Brenner Journal: Cancer Prev Res (Phila) Date: 2011-03
Authors: Massimo Mascolo; Stefania Staibano; Gennaro Ilardi; Maria Siano; Maria Luisa Vecchione; Dario Esposito; Gaetano De Rosa; Giovanni Domenico De Palma Journal: Gastroenterol Res Pract Date: 2012-04-08 Impact factor: 2.260